| Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone‐induced reduction of adult hippocampal neurogenesis JL Mayer, L Klumpers, S Maslam, ER De Kloet, M Joels, PJ Lucassen Journal of neuroendocrinology 18 (8), 629-631, 2006 | 225 | 2006 |
| A brief background on cannabis: From plant to medical indications LE Klumpers, DL Thacker Journal of AOAC International 102 (2), 412-420, 2019 | 136 | 2019 |
| Manipulating brain connectivity with δ9-tetrahydrocannabinol: a pharmacological resting state FMRI study LE Klumpers, DM Cole, N Khalili-Mahani, RP Soeter, ET Te Beek, ... Neuroimage 63 (3), 1701-1711, 2012 | 117 | 2012 |
| Novel Δ9‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ... British journal of clinical pharmacology 74 (1), 42-53, 2012 | 94 | 2012 |
| Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short-and long-term pharmacokinetics JAAC Heuberger, Z Guan, OO Oyetayo, L Klumpers, PD Morrison, ... Clinical pharmacokinetics 54, 209-219, 2015 | 91 | 2015 |
| Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC M Tagen, LE Klumpers British journal of pharmacology 179 (15), 3915-3933, 2022 | 87 | 2022 |
| Peripheral selectivity of the novel cannabinoid receptor antagonist TM 38837 in healthy subjects LE Klumpers, M Fridberg, ML de Kam, PB Little, NO Jensen, HD Kleinloog, ... British Journal of Clinical Pharmacology 76 (6), 846-857, 2013 | 77 | 2013 |
| Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ... British Journal of Clinical Pharmacology 76 (1), 65-77, 2013 | 32 | 2013 |
| Subjective Effects of Ethanol, Morphine, Δ9-Tetrahydrocannabinol, and Ketamine Following a Pharmacological Challenge Are Related to Functional Brain Connectivity D Kleinloog, S Rombouts, R Zoethout, L Klumpers, M Niesters, ... Brain connectivity 5 (10), 641-648, 2015 | 15 | 2015 |
| The risk of chronic psychedelic and MDMA microdosing for valvular heart disease M Tagen, D Mantuani, L van Heerden, A Holstein, LE Klumpers, ... Journal of Psychopharmacology 37 (9), 876-890, 2023 | 10 | 2023 |
| Surinabant, a selective CB (1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ... Br J Clin Pharmacol 76, 65-77, 2013 | 5 | 2013 |
| Pharmacokinetic/pharmaco–dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ9‐tetrahydrocannabinol … Z Guan, LE Klumpers, OO Oyetayo, J Heuberger, JMA van Gerven, ... British Journal of Clinical Pharmacology 81 (4), 713-723, 2016 | 3 | 2016 |
| 304 Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults A Monte, A Gorbenko, J Heuberger, KC Cundy, L Klumpers, ... Annals of Emergency Medicine 82 (4), S133, 2023 | 1 | 2023 |
| Fall 2020 proceedings of the cannabis chemistry subdivision NB Arora, JL von Salm ACS Chemical Health & Safety 28 (2), 73-93, 2021 | 1 | 2021 |
| Novel approaches in clinical development of cannabinoid drugs L Klumpers Neuroimage 63 (3), 1701-1711, 2012 | 1 | 2012 |
| First in human trial of an oral tablet with Delta 9-THC (Namisol (R)) LE Klumpers, JMA van Gerven, TL Beumer EUROPEAN JOURNAL OF NEUROLOGY 17, 493-493, 2010 | 1 | 2010 |
| Pharmacologic resting state-FMRI: effects of cannabis on functional brain connectivity at rest RP Soeter, LE Klumpers, N Khalili-Mahani, MA van Buchem, ... Annual Meeting of the Organization for Human Brain Mapping, Barcelona, Spain, 2010 | 1 | 2010 |
| Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design J Rozanc, LE Klumpers, MA Huestis, M Tagen Cannabis and Cannabinoid Research 9 (2), 437-448, 2024 | | 2024 |
| Pharmacokinetics of Two Nanoemulsion Formulations of Δ8-Tetrahydrocannabinol in Rats M Tagen, LE Klumpers, A Peshkovsky AAPS PharmSciTech 24 (8), 239, 2023 | | 2023 |
| 380 Prediction of a Therapeutically Active Dose of the Cannabinoid Type 1 Receptor Antagonist ANEB-001 for Reversal of Acute Cannabis Intoxication Using a Pharmacokinetic … L Klumpers, A Gorbenko, J Heuberger, K Cundy, GJ Groeneveld, ... Annals of Emergency Medicine 82 (4), S167, 2023 | | 2023 |
Serge A RomboutsLeiden在 lumc.nl 的电子邮件经过验证
